Telix Pharmaceuticals Limited (TLPPF)

Market Cap	3.27B
Revenue (ttm)	664.23M
Net Income (ttm)	10.84M
Shares Out	n/a
EPS (ttm)	0.04
PE Ratio	301.66
Forward PE	212.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,500
Average Volume	2,338
Open	9.24
Previous Close	n/a
Day's Range	9.24 - 9.60
52-Week Range	8.56 - 24.85
Beta	1.22
RSI	49.29
Earnings Date	Jan 15, 2026

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: OTCMKTS
• Ticker Symbol: TLPPF

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.